Articles from TRIANA Biomedicines, Inc.

TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for TRI-611, an investigational molecular glue degrader therapy for the treatment of anaplastic lymphoma kinase–positive (ALK+) non-small cell lung cancer (NSCLC).

TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, today announced that the first patient has been dosed in a Phase 1/2 clinical trial evaluating TRI-611, a novel ALK-fusion molecular glue degrader, in patients with anaplastic lymphoma kinase–positive (ALK+) non-small cell lung cancer (NSCLC).

TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, today announced the successful closing of its oversubscribed $120 million Series B financing round.

Robert A. Copeland, PhD and Adrian M. Senderowicz, MD join Scientific Advisory Board

TRIANA Biomedicines, Inc. (Triana) today announced their launch with $110 million in total funding to establish a best-in-class, scalable platform to discover and develop “molecular glues”. Triana’s platform aims to generate products that stabilize pre-existing or create de novo interactions between two proteins and alter the fate or functionality of the disease target. Molecular glues may allow for the pursuit of highly disease-relevant targets long considered undruggable or inadequately addressed by traditional drug discovery approaches.